Compounds

Details Compounds Compounds

2005-10-04

2005-10-04

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S381000, C514S397000, C514S406000, C514S422000, C514S428000, C546S201000, C548S250000, C548S314700, C548S364100, C548S517000, C548S518000, C548S567000

Reexamination Certificate

active

06951874

ABSTRACT:
The invention provides compounds of general formula (I) wherein Q, R, R2, R4, R5, R6, R7and R8are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy

REFERENCES:
patent: 3203992 (1965-08-01), Kunz et al.
patent: 3577432 (1971-05-01), Helsley
patent: 3755584 (1973-08-01), Plotnikoff et al.
patent: 3775584 (1973-11-01), Plotnikoff et al.
patent: 3818017 (1974-06-01), Janssen et al.
patent: 3894030 (1975-07-01), Janssen et al.
patent: 4029801 (1977-06-01), Cavalla et al.
patent: 4166119 (1979-08-01), Effland et al.
patent: 4264613 (1981-04-01), Regnier et al.
patent: 4338323 (1982-07-01), Regnier et al.
patent: 5576321 (1996-11-01), Krushinski, Jr. et al.
patent: 5614523 (1997-03-01), Audia et al.
patent: 5614533 (1997-03-01), Anderson et al.
patent: 5627196 (1997-05-01), Audia et al.
patent: 5741789 (1998-04-01), Hibschman et al.
patent: 5789402 (1998-08-01), Audia et al.
patent: 37 23 568 (1989-01-01), None
patent: 3723648 (1989-01-01), None
patent: 197 03 131 (1998-07-01), None
patent: 197 55 268 (1999-06-01), None
patent: 0 095 454 (1983-11-01), None
patent: 0 128 007 (1984-12-01), None
patent: 0 496 691 (1992-07-01), None
patent: 0 587 311 (1994-03-01), None
patent: 0 722 941 (1996-07-01), None
patent: 0 903 349 (1999-03-01), None
patent: 2 190 430 (1974-02-01), None
patent: 1368012 (1974-09-01), None
patent: WO 93/25528 (1993-12-01), None
patent: WO 97/23458 (1997-07-01), None
patent: WO 98/32442 (1998-07-01), None
patent: WO 99/25686 (1999-05-01), None
patent: WO 99/31092 (1999-06-01), None
patent: WO 99/65895 (1999-12-01), None
patent: WO 00/35449 (2000-06-01), None
patent: WO 00/35451 (2000-06-01), None
patent: WO 00/53600 (2000-09-01), None
patent: WO/00/58305 (2000-10-01), None
patent: WO 00/69820 (2000-11-01), None
patent: WO 01/14333 (2001-03-01), None
patent: WO 01/43744 (2001-06-01), None
patent: WO 01/44227 (2001-06-01), None
patent: WO 01/87839 (2001-11-01), None
Chou et al. “Pharmacological characteriszation of . . . ” CA 137:336539 (2002).
Archibald et al. “Antiinflammatory 4-acylaminopiperidines” CA 77:34355 (1972).
Cohen et al. “Cytokine function . . . ” CA 125:31527 (1996).
Rubini et al. “Synthesis of isosteric methylene-oxy pseudopipride . . . ” Tetrahedron v.42 pp. 6039045 (1986).
Tomoaki Komai, et al. “Structure-Activity Relationships of HIV-1 PR Inhibitors Containing AHPBA-II. Modification of Pyrrolidine Ring at P1. Proline” Bioorganic & Medicinal Chemistry, vol. 4, No. 8, pp. 1365-1933 (1996).
Manabu Hori Kim D. Janda, “A Soluble Polymer Approach to the “Fishing Out” Principle: Synthesis and Purification of β-Amino Alcohols,” J. Org. Chem, vol. 63, pp. 889-894 (1998).
U.S. Appl. No. 10/311,667, filed Dec. 17, 2002, Eriksson et al.
U.S. Appl. No. 10/468,179, filed Aug. 18, 2003, Brough et al.
U.S. Appl. No. 10/472,412, filed Sep. 16, 2003, Eriksson et al.
Friebe et al., “Piperidinopropyl derivatives and pharmaceutical compositions containing them”CAPLUS94:103172 (1981).
Leclerc et al., “Derivatives Related to Betaxolol with α-and β-Adrenergic Activities”,Arzneim.-Forsch/Drug. Res. 35(11):1357-1367 (1985).
Meurer et al., Discovery of potent human CCR5 antagonists for the treatment of HIV-1 infection-1CAPLUS2000:331722 (2000).
Timmermans et al., “Hypotensive Properties of Benzodioxane Derivatives Structurally Related to R 28935. Comparison of Activity with some Receptor Affinities”,Arh. int. Pharmacodyn. 255:321-3 (1982).
STN International, File CAPLUS, CAPLUS Accession No. 1968.402884.
Marc Payard, et al., “Dérivés N aminométhyles de quelques acides hydroxamiques ä visée anti-inflammatoire,” Eur. J. Med. Chem., vol. 10, No. 2, pp. 125-128 (Mar. Apr. 1975).
Frank Navas III, et al., “The Design and Synthesis of a Hapten for 1.192U90, A Potential Atypical Antipsychotic Agent,” Synthetic Communications, Vol. 26, No. 7, pp. 1411-1421 (1996).
O.M. Zack Howard, et al., “Chemokines: progress toward identifying molecular targets for therapeutic agents,” Trends in Biotechnology, vol. 14, pp. 46-51 (1996).
Joseph Hesselgesser, et al., “Identification and Characterization of Small Molecule Functional Antagonists of the CCR.1 Chemokine Receptor,” The Journal of Biological Chemistry, vol. 2 No. 25, pp. 15687-15692 (1998).
U.S. Appl. No. 10/204,790, filed Aug. 23, 2002, Bodkin et al.
U.S. Appl. No. 10/204,789, filed Jul. 31, 2002, Hansen et al.
U.S. Appl. No. 10/204,754, filed Aug. 23, 2002, Hansen et al.
U.S. Appl. No. 10/311,841, filed Dec. 17, 2002, Eriksson.
U.S. Appl. No. 10/471,499, filed Sep. 11, 2003, Brough et al.
U.S. Appl. No. 10/472,017, filed Sep. 19, 2003, Eriksson et al.
Jon L. Wright et al., “Discovery of Selective Dopamine D4 Receptor Antagonists: 1-Aryloxy-3-(4-Aryloxypiperidinyl)-2-Propanols”, vol. 7, No. 11, Bioorganic & Medicinal Chemistry Letters, 1377-1380 (1997).
Christopher J.Cattanach et al., “Indole Series. IV. Tetrahydro-5H-pyrido[4,3-b]indoles as serotonin antagonists,” J. Chem. Soc. C., vol. 10, pp. 1235-1243 (1968).
Marc Payard et al., “N-Aminomethylated Derivatives of Some Hydroxamic Acids as Anti-Inflammatories,” Eur. J. Med. Chem., pp. 1-10 (Jan. 21, 1975).

Affiliated with

Also associated with

Rating

Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3454766